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ABSTRACT
Kawasaki disease (KD) is a systemic vasculitis that mainly affects children younger than 5 years. Although Dr.
Tomisaku Kawasaki first reported KD over 40 years ago, the cause of the disease remains unknown. Currently, KD
has been diagnosed in more than 60 countries, including those in Asia, the Middle East, Latin America, and Africa, as
well as in North America and Europe. The purpose of this review is to describe the epidemiologic features of
KD—particularly its incidence, seasonality, and the occurrence of coronary artery abnormalities—primarily in Japan
and the United States, but also in Europe and other Asian countries.
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1. INTRODUCTION
Kawasaki disease (KD) is a systemic vasculitis that
mainly affects children younger than 5 years. Although
over 40 years have passed since Dr. Tomisaku Kawasaki
first reported a case series of this disease,1 its cause remains
unknown. Coronary artery abnormalities (CAAs), includ-
ing dilatations and aneurysms, are the most serious
complications of KD. Although KD is a self-limiting
disease in most patients, CAAs develop in about 25% of
untreated patients. Therefore, KD is recognized as a leading
cause of acquired heart disease in children in developed
countries.2
KD has been reported in many countries. In the
United States, the first case series was described by Melish
in 1976.3 Currently, more than 60 countries in Asia, the
Middle East, the Americas, Africa, and Europe have reported
KD cases.4 The purpose of this review is to describe the
epidemiologic features of KD—with a focus on incidence,
seasonality, and CAAs—in Japan and the United States,
as well as in several European and other Asian countries.
As this is not a systematic review, we cite the published
literature on the descriptive epidemiology of KD. Because
seasonal variation in KD is an important characteristic
of descriptive epidemiology, and the seasonality of KD
is unique, we have chosen to focus on the seasonality of
KD.
Japanese and American Heart Association
guidelines
As the cause of KD is still unknown, it is defined based on its
clinical manifestations. In Japan, the Diagnostic Guidelines
for Kawasaki Disease (Fifth Revised Edition, February 2002)
is widely used.5 The signs and symptoms can be classified
into 2 categories: principal symptoms and other significant
symptoms or findings. The principal symptoms are (1) fever
persisting for 5 or days or longer (including fever that
subsides before the fifth day in response to therapy), (2)
bilateral conjunctival injection, (3) changes in the lips and
oral cavity, (4) polymorphous exanthema, (5) changes in
peripheral extremities, and (6) acute nonpurulent cervical
lymphadenopathy. At least 5 of these 6 principal signs or
symptoms should be present for a diagnosis of KD. However,
KD can be diagnosed if patients with 4 of the principal signs
or symptoms have a coronary artery aneurysm or dilatation, as
determined by 2-dimensional echocardiography or coronary
angiography. In the 2004 American Heart Association
Scientific Statement, a fever persisting 5 days or longer is
necessary for a diagnosis of KD.2 In other words, diagnosis
of KD is based on a fever persisting 5 days or longer and the
presence of at least 4 of the other 5 principal features.
However, the diagnostic criteria defined by the American
Heart Association are comparable to the Japanese diagnostic
guidelines because 99% of patients with KD who were
diagnosed using Japanese diagnostic guidelines also fulfilled
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the fever criterion.6 A diagnosis of incomplete or atypical KD
can be made if echocardiographic evidence of CAAs and
fewer than 4 principal features are present.
2. EPIDEMIOLOGIC FEATURES OF
KAWASAKI DISEASE
2.1 Kawasaki disease incidence
Japan
In Japan, nationwide epidemiologic surveys of KD have been
conducted almost every 2 years since 1970.7 The most recent
survey with published data was conducted in January 2009
(the 20th survey) and included patients who visited hospitals
during 2007–2008. The survey questionnaire and diagnostic
guidelines were mailed to all specialized pediatric hospitals
and general hospitals with a pediatric department having 100
or more beds. The survey method was similar throughout all
the surveys.8 The total number of patients who visited
hospitals during 2007–2008 was 23 337 (boys, 13 523 and
girls, 9814), and the average annual KD incidence during the
2-year period was 216.9 per 100 000 children younger than 5
years (boys, 245.4 and girls, 187.0). The male-to-female ratio
in incidence was 1.31. Among all reported patients during the
2-year period, 88.4% were younger than 5 years, and 67.7%
were younger than 3 years. Age-specific incidence was
highest among children aged 6 to 11 months and was very
low among children aged 0 to 2 months. Among both boys
and girls, incidence rate curves were unimodal. Three large
epidemics were recorded in Japan—in 1979, 1982, and 1986.
Although a similar nationwide epidemic has not been
observed since 1990, the incidence of KD has more than
doubled during the last 2 decades (Figure). The incidence in
2008 (218.6 per 100 000 children younger than 5 years) was
the highest documented to date.
Korea
In Korea, nationwide surveys of KD have been conducted
every 3 years since the 1990s.9 A questionnaire was sent to all
hospitals that had a pediatric residency program. During
2006–2008, the average annual incidence of KD in Korea was
113.1 per 100 000 children younger than 5 years. This is the
second highest incidence of KD in the world. KD incidence
has also been increasing in Korea since 2000. The reason for
the increasing trend in KD incidence in Japan and Korea is
unknown.
Taiwan
An epidemiologic study of KD in Taiwan was conducted
using the database of the National Health Insurance system,
which covers most medical care costs of the Taiwanese
population.10 During 2003–2006, the annual incidence of KD
was 69 per 100 000 for children younger than 5 years in
Taiwan. This rate was the third highest in the world. The male-
to-female ratio was 1.62, which was higher than that in Japan.
China
In China, epidemiologic studies of KD were conducted in
several provinces. In Beijing, a questionnaire and diagnostic
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Figure. Trend in incidence rates of Kawasaki disease by sex in Japan
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to select the hospitals was similar to that used in Japan.11 A
similar survey methodology was used in studies performed in
Shanghai, and a slightly modified survey methodology was
used in Sichuan province. In Beijing, the average annual
incidence of KD during 2000–2004 was 49.4 per 100 000
children younger than 5 years. A significant increasing trend
in KD incidence was observed during the 10-year study period
from 1995–2004.
In Shanghai, a questionnaire and diagnostic guidelines were
sent to 50 hospitals providing pediatric medical care.12 The
average annual incidence during 1998–2002 was 27.3 per
100 000 children younger than 5 years.13 KD incidence
increased to 46.3 per 100 000 children younger than 5 years
from 2003–2007.
In Sichuan province, an epidemiologic study investigated
patients hospitalized with KD in all hospitals in Sichuan
province from 1997–2001.14 The incidence of KD was 7.1 per
100 000 children younger than 5 years during the study
period. The incidence rate increased during each year of the
study period.
In Hong Kong, a retrospective survey and prospective data
collection were combined to assess the epidemiologic features
of KD.15 The incidence in 1997–2000 was higher than that
in 1994–1997 (39 vs 26 per 100 000 children younger than 5
years).
Thailand
A retrospective epidemiologic study of KD was conducted
using the National Registry, which included data from all
major cardiac referral centers in Thailand.16 The incidence of
KD in 1998–2002 ranged from 2.12 to 3.43 per 100 000
children younger than 5 years.
India
An epidemiologic study was conducted using data from 1
tertiary hospital that provided services to all children in
Chandigarh, North India.17 The incidence of KD was 0.51 per
100 000 children younger than 15 years in 1994. The
incidence was calculated for children younger than 15 years
because the median age of this study population was older.
The incidence of KD showed an increasing trend during
1994–2008.
United States
In the United States, passive surveillance of KD has been
conducted since 1976. Information on KD patients is collected
using a standardized case report form that has been revised
over the years. Although reporting of KD patients in the
passive surveillance system is not complete, surveillance
has allowed detection of nationwide KD outbreaks and
monitoring of trends in cardiac complications, including
CAAs. Monitoring trends in the occurrence of cardiac
complications could help identify changes in diagnostic
practices and the efficacy of intravenous immunoglobulin
(IVIG) treatment.18 Passive KD surveillance is supplemented
by periodic analysis of national hospital discharge records.
The most recent analysis, which investigated US
hospitalization data from 2009, showed a hospitalization rate
for KD of 19 per 100 000 children younger than 5 years
(unpublished data). Previous hospitalization rates per 100 000
children younger than 5 years were 20.8 in 2006, 19.6 in
2003, 17.1 in 2000, and 17.5 in 1997, as reported using data
from the Kids Inpatient Database, the largest nationwide
hospitalization database for children.19 Analysis of this
database and other hospitalization databases revealed no
clear evidence for a statistically significant increase in the
incidence of KD in the United States for over 2 decades.19,20
In contrast, for reasons that are not well understood, a steady
increase in KD incidence has been reported in many other
countries, including Japan.
Studies in the United States have shown a clear variation in
KD incidence by race and ethnicity. Incidence has consistently
been highest among Asians and Pacific Islanders, followed in
descending order by blacks, whites, and American Indians and
Alaska Natives. As compared with whites, incidence is more
than 2.5 times higher among Asians and Pacific Islanders and
about 1.5 times higher among blacks. Although genetic or
environmental factors could have a major role, the basis for
these racial differences in KD incidence is poorly understood.
States with high Asian populations are expected to have a
higher incidence of KD. Hawaii has the highest proportion of
Asian and Pacific Islander populations and has the highest KD
incidence of any US state. In 2010, approximately half of the
1.4 million residents of Hawaii were Asian, native Hawaiian,
or other Pacific Islanders.21 KD incidence in Hawaii is about
2.5 times higher than that reported for the continental United
States.22 During 1996–2006, among children younger than 5
years living in Hawaii, Japanese Americans had the highest
KD incidence by far (210.5 per 100 000), followed by Native
Hawaiians (86.9 per 100 000) and Chinese Americans (83.2
per 100 000). Children classified in the census as Other
Asian (predominantly Korean Americans and Vietnamese
Americans) had a KD incidence of 84.9 per 100 000. The
incidence among Japanese-American children living in
Hawaii was slightly higher than that for Japanese children
living in Japan (184.6 per 100 000 for 2005–2006).22 This
slight discrepancy may reflect differences in diagnostic
practices and surveillance methodology. This high incidence
among Japanese Americans relative to that of other Asian
Americans living in Hawaii strongly indicates that genetic
factors rather than environmental factors have a major role in
the occurrence of KD among these populations. It appears that
children of Japanese ancestry are at highest risk for KD
regardless of their area of residence, ie, in Hawaii or Japan,
which provides strong evidence for the hypothesis that genetic
factors have a crucial role in KD occurrence. Similarly, KD
incidence among whites living in Hawaii is remarkably
similar to that among whites in the continental United States.
In the continental United States, KD incidence differs by
region: the northeast has the highest incidence, although the
differences are not statistically significant.19
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Many studies in the United States have indicated that 75%
to 80% of KD patients are younger than 5 years and have a
median age of approximately 1.5 years. KD incidence in boys
is approximately 1.5 times that of girls. By age, 2-year-old
children had the highest KD incidence (32.6), followed by
those aged 1 year (23.1), 3 years (13.5), and 4 years (10.6).19
In 2006, KD resulted in an estimated $110 million in
hospitalization costs in the United States.
Canada
Since the mid-1990s, periodic systematic surveillance for
KD has been conducted in the province of Ontario, where
approximately 39% of the Canadian population resides.23 KD
incidence among children younger than 5 years was reported
to have increased from 14.4 during 1995–1997 to 26.2 during
2004–2006. However, the incidence appears to have reached a
plateau after 2000, which suggests that increased recognition
of KD explains the rising trend in KD incidence from the
mid-1990s to 2000. A recent study in Ontario reported a
median age at onset of 3.3 years, which was higher than that
reported in the United States.23
Europe
Several studies have estimated the incidence of KD in
England. A doubling of KD incidence from 4.0 in
1991–1992 to 8.1 in 1999–2000 was reported in an analysis
of hospital admission data.24 This doubling was partly
attributed to increased recognition of the disease due to
heightened awareness of the importance of early diagnosis and
treatment.24 Most recently, analysis of hospital admissions
data for England indicated that the KD incidence may
have reached a plateau at around 8.4 per 100 000 children
younger than 5 years.25 As expected, areas with high
proportions of Chinese residents had the highest incidence
of KD.
Studies in Scandinavian countries reported KD incidences
ranging from 4.9 per 100 000 children younger than 5 years
for Denmark (1999–2004),26 6.2 for Sweden (1990–1992),27
and up to 7.2 for Finland (1982–1992).28 KD incidence in
Denmark appears to have increased throughout the 1980s and
1990s, and stabilized after 1999. From June 1981 to March
1982, an outbreak of KD was recorded in Finland, where the
annualized incidence more than quadrupled, reaching 31 per
100 000 children younger than 5 years.29
Elsewhere in Europe, a KD incidence of 15.2 per 100 000
children younger than 5 years was reported in Ireland for
1996–2000, which represents one of the highest reported
incidences on the continent.30 For a 1-year period during
2005–2006, a KD incidence of 9 per 100 000 children was
reported for northern France.31 In one of the earliest KD
studies conducted in Europe, an incidence of 14.7 was
reported in northern Italy during 1981–1982.32
The proportion of KD patients younger than 5 years ranged
from 72% in a study in England to 77% in France. The median
age ranged from 2 years in England and Ireland to 3 years in a
study conducted in northern Italy. Boys consistently had a
higher incidence of KD than girls. KD incidence rates are
summarized in the Table.
2.2 Seasonality
Japan and Asia
In Japan, 2 seasonal peaks of KD incidence have been
documented, in January (winter) and July (summer). The
lowest number of KD patients was consistently reported in
October (fall).
In Korea, where the second highest incidence of KD has
been reported, seasonal occurrence of KD was observed in
June and July (summer) and December and January (winter).9
The peak months of KD occurrence were May to June
(summer) in Taiwan, whereas the lowest incidence was
observed between November and January (winter).10 In
China, 2 peaks of KD incidence were seen (in spring
and summer) in Beijing, whereas the lowest incidence was
observed in December and January.11 KD incidence peaks
in May to August (summer and spring) in Shanghai.12 In
Sichuan province, the highest incidence was observed in
March through May, and the lowest incidence was in
September.14 The peak occurrence of KD was seen in late
spring and summer in Hong Kong.15
United States and Europe
In the United States, a seasonal peak in KD occurrence was
observed in the winter and spring months. The winter peaks
appear to be more prominent in the northeast and southern
regions of the country.18,19 In contrast, no clear seasonal
pattern was observed in Hawaii, owing perhaps to the tropical
climate.22 A prominent seasonal increase in the occurrence of
KD similar to that in the United States was reported in
Ontario, Canada for winter but not spring.23 Analysis of
hospital admissions data in England, Denmark, and Ireland
indicated a similar peak occurrence of KD in the winter
months.25,26,30 The seasonal peak in Finland was in both the
autumn and winter months.28
2.3 Coronary artery abnormalities (CAAs)
Japan and Asia
CAAs are mainly detected by echocardiography.33 In Japan,
the prevalences of coronary artery dilatation, aneurysm, and
giant aneurysm (lumen size ≥8mm) within 30 days after KD
onset were 8.54%, 1.21%, and 0.25%, respectively, during the
2008–2009 study period. These proportions have been
gradually decreasing since the end of the 1990s.8 Patients
who are male, younger than 1 year, older than 5 years, or
resistant to initial IVIG treatment have a higher risk of
developing CAAs.34–36
In Korea, the proportions of coronary artery dilatation
and aneurysms were 16.4% and 2.1%, respectively, during
2006–2008.9 The prevalence of CAAs during that period
declined as compared with 2003–2005.37 The prevalence of
coronary artery aneurysms (defined as ≥3mm in diameter in
children younger than 5 years or ≥4mm in children older than
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5 years) was 7.2% in Taiwan during 2003–2006.10 There was
no significant decrease in the prevalence of coronary artery
aneurysms during the 4-year study period. In Beijing, 20.6%
of patients had CAAs, including dilatations and aneurysms.11
The development of CAAs showed a significant declining
trend during 2000–2004. In Shanghai, the prevalences of
coronary artery dilatation and aneurysms were 15.5% and
4.3%, respectively, during 2003–2007.12 In Sichuan province,
17% of patients with KD developed CAAs.14 The prevalence
of CAAs was 8.5% in the fourth week after KD onset during
1994–2000 in Hong Kong.15 In Thailand, 14.5% of patients
with KD who received IVIG treatment had CAAs.16
United States and Europe
In Ontario, Canada, during 2004–2006, approximately 4% of
KD patients were reported to have developed coronary artery
aneurysms, which was almost a 50% reduction from figures
reported in the mid-1990s.23 In contrast, during a comparable
time period in the United States, the proportion of KD patients
with coronary artery aneurysms remained relatively stable
at about 4%.18 An increase after 1999 in the proportion of
KD patients with coronary artery dilatations observed in the
United States was believed to be due to wider application of
criteria developed by de Zorzi et al, which were published in
1998. The criteria were developed to improve diagnosis of
dilatations by correlating coronary artery internal diameter
with patient body surface area.38 Infants (younger than 1
year), older children (9–17 years), males, Asians and Pacific
Islanders, and Hispanics have a higher risk of developing
CAAs.18 Specifically, the rate for Asians and Pacific Islanders
in the United States was higher than that for whites but similar
to those reported in Japan, Korea, and China.
In European countries, the proportion of KD patients with
CAAs reported were similar to that reported in North America,
eg, 14% with dilatations and aneurysms in Sweden and 4.6%
with aneurysms in Ireland.27,30 Slightly higher proportions of
KD patients with CAAs were reported in recent studies in
Northern France (18%) and Northern Italy (24%).31,39
3. PERSPECTIVES
Initially reported in the 1960s by Dr. Tomisaku Kawasaki
as a distinct entity in the Japanese literature, KD was
independently recognized as a new disease by Melish
and Hicks in Hawaii in the early 1970s. Soon afterwards,
descriptions of similar cases started to appear in the literature,
including case descriptions from Canada (1975), Greece
Table. Reported incidence rates of Kawasaki disease in Asia, Europe, and North America
Region Period Incidencea Data source Citation (reference number)
Asia
Japan 2008 218.6 Nationwide survey Nakamura et al 2010 (8)
Korea 2006–2008 113.1 Nationwide survey Park et al 2011 (9)
Taiwan 2003–2006 69.0 National Health Insurance database Huang et al 2009 (10)
China
Beijing 2004 55.1 Survey of hospitals in Beijing Du et al 2007 (11)
Shanghai 2007 53.3 Survey of hospitals providing pediatric care Ma et al 2010 (12)
Hong Kong 1997–2000 39.0 Retrospective survey and prospective data collection Ng et al 2005 (15)
Sichuan province 2001 9.81 Survey of provincial hospitals Li et al 2008 (14)
India 2007 4.5 Retrospective review of hospital records, Chandigarh,
Northern India
Singh et al 2011 (17)
Thailand 2002 3.4 National Registry for Kawasaki Disease, including data
from major cardiac centers
Durongpisitkul et al 2006 (16)
North America
United States 2009 19.0 Hospitalization data (Kid’s Inpatient Database) CDC, unpublished data
Hawaii 1996–2006 50.4 Hospital discharge records (Hawaii State Inpatient
Database)
Holman et al 2010 (22)
Canada 2004–2006 26.2 Review of medical records from Ontario hospitals and
cardiologists
Lin et al 2010 (23)
Europe
England 1998–2003 8.4 Hospital admissions data Harnden et al 2009 (25)
Ireland 1996–2000 15.2 Hospital discharge records (Ireland’s Hospital In-Patient
Enquiry database)
Lynch et al 2003 (30)
Finland 1992 7.2 Active surveillance and hospital inpatient registry Salo et al 1993 (28)
Denmark 1999–2004 4.9 Hospital discharge data (Danish National Hospital
Register)
Fischer et al 2007 (26)
Sweden 1990–1992 6.2 Report from physicians and inquiries to all pediatrics and
infectious disease departments
Schiller et al 1995 (27)
France 2005–2006 9.0 Prospective survey of pediatric departments in Northern
France
Heuclin et al 2009 (31)
Italy 1981–1982 14.7 Medical record reviews and interviews with patient’s
family, Northeastern Italy
Tamburlini et al 1984 (32)
aIncidence rates were reported per 100000 children <5 years of age, except for India, which was reported per 100000 children <15 years of age.
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(1975), Australia (1976), West Germany (1977), and Belgium
(1977). Patients with illness manifestations resembling
KD were retrospectively identified as early as 1950 in
Tokyo, Japan.40 The occurrence of such cases is believed to
have been rare or nonexistent before 1950. Shibuya et al
hypothesized that KD began in Japan after the Second World
War, perhaps as a result of the introduction of an infectious
agent.40 In contrast, in Western countries, some evidence
indicates that children with illnesses similar to KD may have
been identified since the late 19th century.41 Those cases may
have been misdiagnosed as other childhood conditions such as
infantile polyarteritis nodosa, Stevens Johnson syndrome,
scarlet fever, and acute rheumatic fever. Although acute
rheumatic fever was once a leading cause of acquired heart
disease among children in developed countries, KD now holds
that distinction in many of those countries. It is possible that
KD has been increasingly unmasked by the disappearance of
acute rheumatic fever in the post-antibiotic era.
In addition to possible genetic and environmental factors,
the incidence of KD reported in different regions of the
world can be affected by the survey/surveillance methods
used, clinical diagnostic and treatment practices, physician
awareness of KD, the data sources used to estimate incidence,
the occurrence of KD clusters and outbreaks, and the
population used to estimate incidence. Because nationwide
epidemiologic surveys of KD have been conducted in a
small number of countries, the results of those surveys were
not always generalizable. In some countries, lack of KD
awareness may distort the accuracy of reported incidences of
KD. For instance, the reported KD incidences in Thailand and
India are much lower than those in European countries, and
KD was recently detected for the first time in Mongolia, in 9
patients.42 As awareness of this disease increases among
physicians, incidence is expected to increase. Continuous
monitoring of KD is critical to better understand the global
extent of the disease.
Nationwide KD outbreaks have been documented in several
countries, including Japan in 1979, 1982, and 1986, the
United States in 1984–1985, Canada in the early 1980s, and
Finland in 1981.29 Given the lack of knowledge regarding
the etiology of KD, the factors that may have contributed to
the occurrence of these outbreaks are poorly understood.
Evidence from several countries shows that KD occurs in
clusters and community-wide outbreaks. Population density
and climatic factors have been shown to have a role in
the occurrence of KD and might facilitate the occurrence of
KD outbreaks. Taken together, these characteristics and the
seasonal occurrence of KD indicate that the disease may be
caused by an infectious agent or agents that remain elusive.
Disease susceptibility is thought to be an important factor in
KD occurrence. The incidence of KD is high in Japan, Korea,
and Taiwan, but it is low in North America and European
countries. Asian ethnicity is a well-known risk factor for the
occurrence of KD in Hawaii and the continental United States,
indicating that genetic susceptibility may have a role in the
occurrence of KD.
The introduction of IVIG as a mainstay treatment for KD
has dramatically reduced the rate of CAAs in many countries.
Thus, delayed diagnosis and treatment might result in a higher
rate of CAAs. IVIG fails to ameliorate KD symptoms in up to
20% of KD patients. These patients are at a higher risk of
developing cardiac complications and should be promptly
retreated with a second dose of IVIG or other appropriate
treatment to reduce the occurrence of cardiac complications.
Identification of the causative agent of KD should facilitate
prompt diagnosis and more specific treatment, leading to
further reductions in morbidity and mortality. Additional
studies should continue to focus on identifying the causative
agent of KD, increasing understanding of the environmental
and genetic factors that affect disease susceptibility, and,
possibly, identifying disease markers that aid in early
diagnosis of KD patients with incomplete or atypical
presentation of the disease.
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